Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Amifostine Followed by High-Dose Escalation of Melphalan With Stem Cell Reconstitution for Patients With Primary Systemic Amyloidosis

NCT00052884 is registered in ClinicalTrials.gov with Eastern Cooperative Oncology Group as lead sponsor.

NCT NCT00052884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00052884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Amifostine Followed by High-Dose Escalation of Melphalan With Stem Cell Reconstitution for Patients With Primary Systemic Amyloidosis
Lead sponsor
Eastern Cooperative Oncology Group
Phase
Phase 1
Overall status
Terminated
Start date
January 22, 2004
Completion date
March 31, 2011
Enrollment
8 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

drug/agent toxicity by tissue/organ, multiple myeloma and plasma cell neoplasm